New hope for Hard-to-Treat multiple myeloma: IBI3003 trial launches
Disease control
Not yet recruiting
This study tests a new drug called IBI3003 in people with multiple myeloma that has returned or stopped responding to other treatments. The goal is to find the safest and most effective dose and see how well it controls the cancer. About 360 adults will take part in this early-ph…
Phase: PHASE1, PHASE2 • Sponsor: Fortvita Biologics (USA)Inc. • Aim: Disease control
Last updated May 26, 2026 04:17 UTC